Cart
sales@molnova.com
KPLH1130
CAS No. 906669-07-6
KPLH1130( —— )
Catalog No. M24944 CAS No. 906669-07-6
KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 205 | In Stock |
|
| 10MG | 332 | In Stock |
|
| 25MG | 560 | In Stock |
|
| 50MG | 797 | In Stock |
|
| 100MG | 1071 | In Stock |
|
| 500MG | 2187 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKPLH1130
-
NoteResearch use only, not for human use.
-
Brief DescriptionKPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses.
-
DescriptionKPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPDK
-
RecptorPDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number906669-07-6
-
Formula Weight283.28
-
Molecular FormulaC15H13N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:130 mg/mL (458.91 mM; Need ultrasonic)
-
SMILESO=C1NN=C(C2=CC=C(O)C=C2O)N1C3=CC=C(C)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Min BK, et al. Pyruvate Dehydrogenase Kinase Is a Metabolic Checkpoint for Polarization of Macrophages to the M1 Phenotype. Front Immunol. 2019 May 7;10:944.
molnova catalog
related products
-
OSU-03012
OSU-03012 (AR-12) is a novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 5 uM.
-
6-Bromo-4-methoxypyr...
6-Bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile is a PDK1 inhibitor with anticancer and antiproliferative activity that can be used to study angiosarcoma, adenocarcinoma, multiple myeloma, psoriasis, prostate cancer, and Alzheimer's disease.
-
JX06
JX06, a potent, selective and covalent PDK inhibitor, inhibits PDK1, PDK2 and PDK3 with IC50 of 49 nM, 101 nM and 313 nM respectively.
